Compare KLIC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLIC | LQDA |
|---|---|---|
| Founded | 1951 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.5B |
| IPO Year | 2004 | 2020 |
| Metric | KLIC | LQDA |
|---|---|---|
| Price | $89.84 | $89.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $54.67 | $41.00 |
| AVG Volume (30 Days) | 953.9K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 100.32 | 51.81 |
| EPS | ★ 2.06 | 0.52 |
| Revenue | ★ $654,081,000.00 | $158,320,000.00 |
| Revenue This Year | $45.81 | $278.87 |
| Revenue Next Year | $11.35 | $57.13 |
| P/E Ratio | ★ $95.76 | $171.38 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $34.56 | $19.02 |
| 52 Week High | $135.80 | $91.36 |
| Indicator | KLIC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 64.27 |
| Support Level | $81.62 | $31.99 |
| Resistance Level | $89.59 | $91.10 |
| Average True Range (ATR) | 6.25 | 4.89 |
| MACD | -0.90 | 0.01 |
| Stochastic Oscillator | 8.78 | 89.86 |
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.